Riskpilot← Back to searchSign inGet full accessChosa ApS
APSActiveCVR 43134477Puggaardsgade 17, 2. tvManufacture of pharmaceutical preparations · NACE 2120Est. 20225 employeeswww.chosa.bio
Revenue 2025
DKK -2,1M
+89% vs 2024
EBITDA margin
133.3%
-136% vs 2024
Equity ratio
38.5%
Financial strength
Net profit 2025
DKK -2,6M
+27% vs 2024
| Revenue | DKK -2,1M | +89% |
| EBITDA | DKK -2,8M | -136% |
| Net profit | DKK -2,6M | +27% |
| Total assets | DKK 13,4M | +20% |
| Equity | DKK 5,2M | -31% |
| Employees | 5 | — |
Legal name
Chosa ApS
CVR number
43134477
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
18. marts 2022
Share capital
DKK 9.873.960
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede direktion, eller af to direktører i forening.
Company purpose
Virksomhedens formål er at udvikle og erhvervsmæssigt udnytte kræftbekæmpende behandlinger og andre aktiviteter, som kan forbindes med kræftbekæmpende behandlinger samt hermed beslægtet virksomhed.
Address
Puggaardsgade 17, 2. tv
Phone
+4561616641
Email
claus_frisenberg@hotmail.com
Website
www.chosa.bio
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | -467 | -1.543 | -1.131 | -2.136 |
| Staff expenses | -0 | -0 | -75 | -711 |
| EBITDA | -467 | -1.543 | -1.206 | -2.847 |
| Depreciation & amort. | -350 | -500 | -1.167 | -500 |
| EBIT | -817 | -2.043 | -2.373 | -3.347 |
| Net financials | -0 | 75 | 63 | 20 |
| Profit before tax | -817 | -1.967 | -2.310 | -3.326 |
| Tax | -102 | 102 | 1.277 | -694 |
| Net profit | -715 | -2.070 | -3.587 | -2.632 |
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 7.949 | 10.295 | 11.189 | 13.427 |
| Equity | 7.761 | 8.991 | 7.485 | 5.175 |
| Long-term debt | 0 | 936 | 2.477 | 5.321 |
| Short-term debt | 188 | 368 | 1.228 | 2.931 |
| Total debt | 188 | 1.304 | 3.705 | 8.252 |
EBITDA margin
-284667900.0%
This company
15.8%
Market median
-1801695670% vs market
20222025
Equity ratio
38.5%
This company
38.2%
Market median
+1% vs market
20222025
Return on equity
-50.9%
This company
18.4%
Market median
-377% vs market
20222025
Net profit margin
-263202400.0%
This company
8.1%
Market median
-3249412446% vs market
20222025
Asset turnover
-0.16×
This company
1.12×
Market median
-114% vs market
20222025
Debt / equity
1.59×
This company
0.62×
Market median
-156% vs market
20222025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-03-18 – 2022-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
NG Management | Management | 2022 | — | — |
CF Management | Management | 2022 | — | — |
PB Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
SV | Founder | 2022 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2023 | |
| Individual | 10.0% | 10.0% | 2022 | |
| Individual | 5.0% | 5.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Chosa ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Neil Goldsmith | Management | 0 companies |
| Claus Frisenberg Pedersen | Management | 0 companies |
| Peter Buhl | Chief Executive Officer | 0 companies |
| SH Verwaltungsgesellschaft mbH | Founder | 0 companies |